Prescription Pattern of Intravenous Fosfomycin in a Provincial Hospital in Thailand
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: In Thailand, active antibiotics against Gram-negative bacteria are limited. The re-emergence of intravenous (IV) fosfomycin is an alternative. IV fosfomycin has broad-spectrum activity, relative safety, and availability. The limitations of the clinical use of IV fosfomycin include the lack of susceptibility reports and unclear dosing. Therefore, this study was designed to examine the prescription pattern of IV fosfomycin in Chonburi Hospital, a provincial hospital in Thailand. Materials and methods: A retrospective descriptive study involving in-patients aged ≥18 years who received IV fosfomycin between February 2019 and January 2020. Data were collected from the electronic patient records. Results: Of 265 patients, 254 (95.8%) and 11 (4.2%) received IV fosfomycin for treatment and prophylaxis, respectively. IV fosfomycin was prescribed for empirical and definitive treatment. All 166 organisms were Gram-negative bacteria (GNB), including Enterobacterales (47.0%), Acinetobacter baumannii (44.0%), and Pseudomonas aeruginosa (9.0%). Moreover, 141 (87.6%) isolates were carbapenem-resistant GNB (CR-GNB). The most commonly used IV fosfomycin regimen contained colistin or aminoglycosides. Furthermore, 35.3% of the combination regimens contained one active antibiotic. The appropriate dosage of IV fosfomycin for treating urinary tract infection was 71.8%. The 14-day all-cause mortality rate in CR-GNB was 45.0%. Conclusion: IV fosfomycin is reserved for secondary use in treating nosocomial infection with resistant GNB. It is used synergistically with other antibiotics. At least one active antibiotic and the optimal fosfomycin dosage should be considered. An antimicrobial stewardship program should be implemented for the optimal use of fosfomycin.
Abstract
Background: In Thailand, active antibiotics against Gram-negative bacteria are limited. The re-emergence of intravenous (IV) fosfomycin is an alternative. IV fosfomycin has broad-spectrum activity, relative safety, and availability. The limitations of the clinical use of IV fosfomycin include the lack of susceptibility reports and unclear dosing. Therefore, this study was designed to examine the prescription pattern of IV fosfomycin in Chonburi Hospital, a provincial hospital in Thailand. Materials and methods: A retrospective descriptive study involving in-patients aged ≥18 years who received IV fosfomycin between February 2019 and January 2020. Data were collected from the electronic patient records. Results: Of 265 patients, 254 (95.8%) and 11 (4.2%) received IV fosfomycin for treatment and prophylaxis, respectively. IV fosfomycin was prescribed for empirical and definitive treatment. All 166 organisms were Gram-negative bacteria (GNB), including Enterobacterales (47.0%), Acinetobacter baumannii (44.0%), and Pseudomonas aeruginosa (9.0%). Moreover, 141 (87.6%) isolates were carbapenem-resistant GNB (CR-GNB). The most commonly used IV fosfomycin regimen contained colistin or aminoglycosides. Furthermore, 35.3% of the combination regimens contained one active antibiotic. The appropriate dosage of IV fosfomycin for treating urinary tract infection was 71.8%. The 14-day all-cause mortality rate in CR-GNB was 45.0%. Conclusion: IV fosfomycin is reserved for secondary use in treating nosocomial infection with resistant GNB. It is used synergistically with other antibiotics. At least one active antibiotic and the optimal fosfomycin dosage should be considered. An antimicrobial stewardship program should be implemented for the optimal use of fosfomycin.
참고문헌 (40)
- "About the antimicrobial resistance course series"[URL]
- "Thailand (NARST). Antimicrobial resistance"[URL]
- Performance standards for antimicrobial susceptibility testing: 29th ed, "Clinical and Laboratory Standards Institute (CLSI)", CLSI, ~, pp.CLSI supplement M100 (2019)
- "Breakpoint tables for interpretation of MICs and zone diameters. Version 12.0, valid from 2022-01-01"[URL]
- Falagas ME, "Fosfomycin", Clin Microbiol Rev, 29, pp.321~347 (2016)
- Hashemian SMR, "Fosfomycin : the characteristics, activity, and use in critical care", Ther Clin Risk Manag, 15, pp.525~530 (2019)
- Dijkmans AC, "Pharmacological, clinical and future perspectives", Antibiotics(Basel), 6, pp.24~ (2017)
- Reffert JL, "Fosfomycin for the treatment of resistant gram-negative bacterial infections. Insights from the Society of Infectious Diseases Pharmacists", Pharmacotherapy, 34, pp.845~857 (2014)
- Russo A, "Efficacy of a fosfomycin-containing regimen for treatment of severe pneumonia caused by multidrug-resistant Acinetobacter baumannii : a prospective, observational study", Infect Dis Ther, 10, pp.187~200 (2021)
- Kaye KS, "Fosfomycin for injection(ZTI-01)versus piperacillin-tazobactam for the treatment of complicated urinary tract infection including acute pyelonephritis : ZEUS, a phase 2", 3 randomized trial, 2019, pp.69, 2045~2056
- Leelawattanachai P, "Evaluation of intravenous fosfomycin disodium dosing regimens in critically ill patients for treatment of carbapenem-resistant enterobacterales infections using Monte Carlo simulation", Antibiotics(Basel), 9, pp.615~ (2020)
- "Pediatric and Neonatal Lexi-Drugs Online" (2021)[URL]
- Putensen C, "Current clinical use of intravenous fosfomycin in ICU patients in two European countries", Infection, 47, pp.827~836 (2019)
- Zirpe KG, "A real-world study on prescription pattern of fosfomycin in critical care patients", Indian J Crit Care Med, 25, pp.1055~1058 (2021)
- Grabein B, "Intravenous fosfomycin-back to the future. Systematic review and meta-analysis of the clinical literature", Clin Microbiol Infect, 23, pp.363~372 (2017)
- Lertsrisatit Y, "In vitro activity of colistin monoand combination therapy against colistin-resistant Acinetobacter baumannii, mechanism of resistance, and clinical outcomes of patients infected with colistin-resistant A. baumannii at a Thai university hospital", Infect Drug Resist, 10, pp.437~443 (2017)
- Leelasupasri S, "Antimicrobial susceptibility among colistin, sulbactam, and fosfomycin and a synergism study of colistin in combination with sulbactam or fosfomycin against clinical isolates of carbapenem-resistant Acinetobacter baumannii", J Patho, 2018, pp.3893492~ (2018)
- Asuphon O, "Optimizing intravenous fosfomycin dosing in combination with carbapenems for treatment of Pseudomonas aeruginosa infections in critically ill patients based on pharmacokinetic", pharmacodynamic(PK, Int J Infect Dis, pp.2016, 50[DOI]
- Samonis G, "Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates", Eur J Clin Microbiol Infect Dis, 31, pp.695~701 (2012)
- Kastoris AC, "Synergy of fosfomycin with other antibiotics for Gram-positive and Gram-negative bacteria", Eur J Clin Pharmacol, 66, pp.359~368 (2010)
- Saelim Weerayuth, "Colistin plus Sulbactam or Fosfomycin against Carbapenem-Resistant Acinetobacter baumannii: Improved Efficacy or Decreased Risk of Nephrotoxicity?", Infection and Chemotherapy, 53(1), pp.128~140 (2021), 대한감염학회[DOI]
- Cebrero-Cangueiro T, "Efficacy of fosfomycin and its combination with aminoglycosides in an experimental sepsis model by carbapenemase-producing Klebsiella pneumoniae clinical strains", Front Med(Lausanne), 8, pp.615540~ (2021)
- Antonello RM, "Fosfomycin as partner drug for systemic infection management. A systematic review of its synergistic properties from in vitro and in vivo studies", Antibiotics(Basel), 9, pp.500~ (2020)
- Papst L, "Antibiotic treatment of infections caused by carbapenem-resistant Gram-negative bacilli : an international ESCMID cross-sectional survey among infectious diseases specialists practicing in large hospitals", Clin Microbiol Infect, 24, pp.1070~1076 (2018)
- Du X, "Predictors of mortality in patients infected with carbapenem-resistant Acinetobacter baumannii : a systematic review and meta-analysis", Am J Infect Control, 47, pp.1140~1145 (2019)
- Pudpong K, "Association between types of carbapenemase and clinical outcomes of infection due to carbapenem resistance enterobacterales", Infect Drug Resist, 15, pp.3025~3037 (2022)
- Leão AC, "Acinetobacter spp. are associated with a higher mortality in intensive care patients with bacteremia : a survival analysis", BMC Infect Dis, 16, pp.386~ (2016)
- Lodise TP, "All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections : a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies", Expert Rev Anti Infect Ther, 20, pp.707~719 (2022)
- Ungthammakhun C, "Clinical outcomes of colistin in combination with either 6-G sulbactam or carbapenems for the treatment of extensively drug-resistant Acinetobacter baumannii pneumonia with high MIC to sulbactam, a prospective cohort study", Infect Drug Resist, 12, pp.2899~2904 (2019)
- "IDSA guidance on the treatment of antimicrobial-resistant Gram-negative infections: Version 2.0"[URL]
- Sirijatuphat R, "Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections", Antimicrob Agents Chemother, 58, pp.5598~5601 (2014)
- "IDSA guidance on the treatment of antimicrobial resistant Gram-negative infections: Version 1.0"[URL]
- Laolerd W, "Carbapenemase-producing carbapenem-resistant enterobacteriaceae from Bangkok, Thailand, and their detection by the darba NP and modified carbapenem inactivation method tests", Microb Drug Resist, 24, pp.1006~1011 (2018)
- Nasomsong W, "The potential use of ceftazidime-avibactam against carbapenem resistant Klebsiella pneumoniae clinical isolates harboring different carbapenemase types in a Thai University hospital", Drug Des Devel Ther, 15, pp.3095~3104 (2021)
- Prawang A, "2284. Treatment and clinical outcomes among infected patients with colistin-resistant Klebsiella pneumoniae bacteremia", Open Forum Infect Dis, 6(Suppl 2), pp.S782~S783 (2019)
- Ruiz Ramos J, "Fosfomycin in infections caused by multidrug-resistant Gram-negative pathogens", Rev Esp Quimioter, 32(Suppl 1), pp.45~54 (2019)
- Kanchanasurakit Sukrit, "Fosfomycin Dosing Regimens based on Monte Carlo Simulation for Treated Carbapenem-Resistant Enterobacteriaceae Infection", Infection and Chemotherapy, 52(4), pp.516~529 (2020), 대한감염학회[DOI]
- Bratzler DW, "Clinical practice guidelines for antimicrobial prophylaxis in surgery", Am J Health Syst Pharm, 70, pp.195~283 (2013)
- Ishizaka K, "Randomized prospective comparison of fosfomycin and cefotiam for prevention of postoperative infection following urological surgery", J Infect Chemother, 13, pp.324~331 (2007)
- Shinagawa N, "Prophylactic effect of fosfomycin on postoperative infection in gastroenterological surgery", Jpn J Antibiot, 59, pp.417~427 (2006)